Help us: Donate
Follow us on:
×

Category: Interviews

February 11, 2020
At the recent Longevity Therapeutics Conference in San Francisco, we had the chance to interview Lewis Gruber of SIWA Therapeutics and discuss his company's senotherapeutic approach to cancer and senescent cells. He was accompanied by his wife, Misty, who is the CFO of SIWA. Many of our readers are familiar with CAR-T immunotherapy, which has...
February 10, 2020
At the recent Longevity Therapeutics Conference in San Francisco, we had the chance to interview Hanadie Yousef, the co-founder and CEO of Juvena Therapeutics. Juvena is isolating proteins from embryonic stem cells that promote tissue regrowth. Can you describe in more detail Juvena's approach to developing protein therapeutics that promote tissue regeneration in the elderly?...
February 05, 2020
We were at the recent Longevity Therapeutics Conference in San Francisco, and we had the opportunity to interview Irina and Michael Conboy from UC Berkeley about their pioneering work on blood factors and aging. Irina is a member of our Scientific Advisory Board, and the Conboys' work is well-known to rejuvenation advocates, as they are...
December 17, 2019
We had the opportunity to interview Greg Potter, Ph.D., a researcher of lifestyle factors in health throughout life, at Biohacking Conference Moscow, which was hosted at the Congress Centre Technopolis Moscow on September 19th. In a provocative 2017 publication, Serge Faguet claimed to have spent $200,000 on becoming healthier and happier through biohacking; since then,...
December 04, 2019
If humans ever reach an average lifespan of well over 100 years, what is going to happen? Are we going to be bored with such long lives? "Well," says Prof. Brian Kennedy of the National University of Singapore, "If you ask me: 'Do I want to have cancer at 75? Do I want have Alzheimer’s...
November 18, 2019
Is the focus on senolytics, drugs that eliminate senescent cells, potentially damaging for longevity? In this interview, Dr. Michael Fossel, who has focused his research on telomeres and the development of telomerase therapy for decades, discusses the potential downsides of senolytics and the promise of telomerase therapy for treating age-related diseases. Senescent cells no longer...